- $257.51m
- $151.24m
- $53.74m
Homology plummets on merger with privately held Q32 Bio
Brief: Homology Medicines Subject To Execution Of Deal With Q23 Bio
Brief: Q32 Bio And Homology Medicines Announce Merger Agreement
Brief: Homology Medicines Q3 basic EPS USD -0.57
Brief: Homology Medicines Q2 net income USD -35.044 million
Homology Medicines Inc reports results for the quarter ended in June - Earnings Summary
Homology Medicines Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Homology Medicines Announces Plan To Evaluate Strategic Options For The Company And Its Genetic Medicines Programs
Brief: Homology Medicines Announces Encouraging Initial Data From First Dose Level In The PheEDIT Trial
Brief: Homology Medicines Inc Currently Estimates That It Will Incur Approximately $6.8 Million In Charges In Connection With Reduction In Force
Homology Medicines Inc reports results for the quarter ended in March - Earnings Summary
U.S. RESEARCH ROUNDUP-Allakos, Virtu Financial, Walt Disney
Brief: Homology Medicines Reports First Quarter 2023 Financial Results
Brief: Homology Medicines Announces Presentations On Design Of Ongoing Gene Editing And Gene Therapy Trials For Pku And Hunter Syndrome At Acmg Annual Clinical Genetics Meeting
U.S. RESEARCH ROUNDUP-Brown-Forman, Lam Research, PPG Industries
Brief: Homology Medicines Inc Files For Mixed Shelf Offering Of Up To $250 Million - SEC Filing
Brief: Homology Medicines Reports Fourth Quarter And Full Year 2022 Results
Brief: Homology Medicines Provides Update On pheEDIT And juMPStart Clinical Trials
U.S. RESEARCH ROUNDUP- Allete, Cisco, Yeti Holdings